Homology Exec Sam Rasty to Depart for CEO Job at Platelet BioGenesis

Sam Rasty, chief operating officer of Homology Medicines (NASDAQ: [[ticker:FIXX]]), is leaving to join Platelet BioGenesis as president and CEO. In a securities filing, Bedford, MA-based Homology said Rasty’s last day will be July 12. Before joining Homology in 2016, Rasty was vice president and head of new products at Shire. Homology, a developer of genetic medicines, raised $144 million in an IPO last year. Cambridge, MA-based Platelet BioGenesis is developing a way to produce platelets from stem cells.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.